Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: infectious disease vaccines - VaxInnate

Drug Profile

Research programme: infectious disease vaccines - VaxInnate

Alternative Names: flagellin.AvHA; flagellin.AvM2e; Hemagglutinin (HA)-based pandemic influenza vaccines - VaxInnate; Hemagglutinin (HA)-based seasonal influenza vaccines - VaxInnate; Human papillomavirus (HPV) vaccine - VaxInnate; Respiratory syncytial virus (RSV) infections - VaxInnate; Swine flu vaccine - VaxInnate

Latest Information Update: 11 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VaxInnate
  • Class Bacterial vaccines; Influenza A vaccines; Papillomavirus vaccines; Recombinant fusion proteins; Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Clostridium difficile infections; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Respiratory syncytial virus infections

Most Recent Events

  • 08 Oct 2015 Preclinical trials in Clostridium difficile infections in USA (Parenteral)
  • 24 Feb 2011 VaxInnate receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Recombinant influenza vaccines in USA
  • 13 Jan 2010 Swine flu vaccine licensed to Biological E in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top